Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
MMWR Morb Mortal Wkly Rep ; 65(2): 36-7, 2016 Jan 22.
Article in English | MEDLINE | ID: mdl-26797167

ABSTRACT

Voluntary medical male circumcision (VMMC) decreases the risk for female-to-male HIV transmission by approximately 60%, and the President's Emergency Plan for AIDS Relief (PEPFAR) is supporting the scale-up of VMMC for adolescent and adult males in countries with high prevalence of human immunodeficiency virus (HIV) and low coverage of male circumcision. As of September 2015, PEPFAR has supported approximately 8.9 million VMMCs.


Subject(s)
Circumcision, Male/adverse effects , HIV Infections/prevention & control , Tetanus/diagnosis , Voluntary Programs , Adolescent , Adult , Africa, Eastern , Africa, Southern , Child , Humans , Male , Middle Aged , Young Adult
2.
MMWR Morb Mortal Wkly Rep ; 63(13): 285-91, 2014 Apr 04.
Article in English | MEDLINE | ID: mdl-24699765

ABSTRACT

In 2008, the 46 member states of the World Health Organization (WHO) African Region (AFR) adopted a measles preelimination goal to reach by the end of 2012 with the following targets: 1) >98% reduction in estimated regional measles mortality compared with 2000, 2) annual measles incidence of fewer than five reported cases per million population nationally, 3) >90% national first dose of measles-containing vaccine (MCV1) coverage and >80% MCV1 coverage in all districts, and 4) >95% MCV coverage in all districts by supplementary immunization activities (SIAs). Surveillance performance objectives were to report two or more cases of nonmeasles febrile rash illness per 100,000 population, one or more suspected measles cases investigated with blood specimens in ≥80% of districts, and 100% completeness of surveillance reporting from all districts. This report updates previous reports and describes progress toward the measles preelimination goal during 2011-2012. In 2012, 13 (28%) member states had >90% MCV1 coverage, and three (7%) reported >90% MCV1 coverage nationally and >80% coverage in all districts. During 2011-2012, four (15%) of 27 SIAs with available information met the target of >95% coverage in all districts. In 2012, 16 of 43 (37%) member states met the incidence target of fewer than five cases per million, and 19 of 43 (44%) met both surveillance performance targets. In 2011, the WHO Regional Committee for AFR established a goal to achieve measles elimination by 2020. To achieve this goal, intensified efforts to identify and close population immunity gaps and improve surveillance quality are needed, as well as committed leadership and ownership of the measles elimination activities and mobilization of adequate resources to complement funding from global partners.


Subject(s)
Disease Eradication , Measles/epidemiology , Measles/prevention & control , Population Surveillance , Africa/epidemiology , Genotype , Humans , Immunization Programs , Incidence , Measles Vaccine/administration & dosage , Measles virus/genetics , Vaccination/statistics & numerical data
3.
J Infect Dis ; 204 Suppl 1: S289-98, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21666176

ABSTRACT

Since 1997, when the goal of interrupting measles transmission by 2010 was adopted, substantial progress has been made toward the elimination of measles in the Eastern Mediterranean Region (EMR). For the 22 EMR member countries, routine coverage with the first dose of a measles-containing vaccine (MCV) increased from 70% in 1997 to 82% in 2009. All 22 countries conducted measles catch-up vaccination campaigns during 1994-2009, and most conducted follow-up campaigns as needed. Of the 22 EMR countries, 19 have established case-based surveillance for measles with laboratory confirmation. Reported measles cases decreased by 86% during 1998-2008, and estimated measles mortality decreased by 93% during 2000-2008, accounting for 17% of global measles mortality reduction during that period. Despite these successes, several significant challenges remain, and the EMR will not be able to achieve measles elimination by the end of 2010. Achieving and maintaining high population immunity with 2 doses of MCV, improving sensitive case-based surveillance, identifying and vaccinating high-risk subpopulation groups, and appropriately responding to outbreaks are key steps needed to achieve the goal.


Subject(s)
Measles Vaccine/administration & dosage , Measles/epidemiology , Measles/prevention & control , Adolescent , Africa/epidemiology , Child , Child, Preschool , Humans , Immunization Programs , Immunization Schedule , Infant , Mediterranean Region/epidemiology , Middle East/epidemiology , Population Surveillance , Time Factors , Young Adult
4.
J Infect Dis ; 204 Suppl 1: S305-11, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21666178

ABSTRACT

Measles is still one of the most common infectious killers of children in the world, especially in developing countries. In Iran, during the prevaccine era, 150,000-500,000 cases of measles were reported annually, with a death rate of 10%-15%. After the establishment of Expanded Program on Immunization program in 1984, vaccination rates for the first and second doses of measles vaccine increased to >90% by the mid-1990s, and the number of measles cases decreased to 2652 in 1996. In response to increased numbers of cases in older age groups during 1996-2002, a nationwide measles-rubella vaccination campaign was conducted in 2003, and 33,100,000 persons (99%) aged 5-25 years were vaccinated. During 2004-2009, 221 laboratory-confirmed measles cases (<1 case per million population) were detected, primarily in rural areas and among migrant groups who traveled to or came from high-incidence countries. High routine immunization coverage, low disease incidence, and surveillance system data suggest that interruption of endemic virus transmission might have already been achieved in Iran, but challenges remain and continued efforts are needed to sustain this accomplishment.


Subject(s)
Measles Vaccine/administration & dosage , Measles/epidemiology , Measles/prevention & control , Adolescent , Adult , Child , Child, Preschool , Communicable Disease Control/organization & administration , Disease Outbreaks/prevention & control , Female , Genotype , Humans , Immunization Programs , Incidence , Infant , Iran/epidemiology , Male , Measles virus/classification , Measles virus/genetics , Measles virus/immunology , Measles-Mumps-Rubella Vaccine/administration & dosage , Population Surveillance , Young Adult
5.
J Infect Dis ; 204 Suppl 1: S299-304, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21666177

ABSTRACT

Measles was a leading cause of infant and child morbidity and mortality in Bahrain before the introduction of measles vaccine in 1974. With the establishment of the Expanded Program on Immunization (EPI) in 1981 and the introduction of a second dose of measles vaccine in 1985, coverage for first and second doses of measles vaccine increased to 94% by 1997 and has been sustained >97% since 2001. Measles, mumps, and rubella (MMR) immunization campaigns targeting 12-year-old students were conducted annually during 1998-2006 and achieved coverage of >95%. As a result, the incidence of measles in Bahrain has declined markedly over the past 4 decades, to 2.7 cases per million persons in 2009. Recent confirmed measles cases have occurred sporadically, in undervaccinated children or in infants too young or adults too old to receive measles vaccine. Bahrain has made significant progress toward measles elimination by sustaining high immunization coverage and strengthening case-based measles surveillance activities. Further success will depend on improved identification and immunization of undervaccinated expatriate workers and their families.


Subject(s)
Measles Vaccine/administration & dosage , Measles/epidemiology , Measles/prevention & control , Adolescent , Adult , Bahrain/epidemiology , Child , Child, Preschool , Female , Humans , Immunization Programs , Infant , Male , Measles/mortality , Measles-Mumps-Rubella Vaccine/administration & dosage , Time Factors , Young Adult
6.
J Infect Dis ; 204 Suppl 1: S312-7, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21666179

ABSTRACT

Despite enormous challenges, Somalia has been successfully implementing accelerated measles control activities since 2005. Through innovative strategies and with the support of local and international partners, the country has shown potentials of implementing measles mortality reduction activities in complex emergencies. Measles incidence has been reduced by >80% after the measles catch-up campaigns of 2005-2007, and national reported measles routine immunization coverage with first dose measles containing vaccine has reached 59% for the first time in 2009. However, the near collapse of the health care system and the ongoing insecurity continue to hamper the implementation of recommended measles control and elimination strategies in some parts of the country, making these achievements fragile. Somalia exemplifies the challenges in meeting measles elimination goals in the World Health Organization Eastern Mediterranean region. As the region is entering its 2010 measles elimination goals, it appears necessary to establish realistic and flexible interim goals for measles control in Somalia that will take into consideration the specificities of the country. Maintaining flexibility in conducting field operations, securing financial resources, multiplying opportunities for measles vaccination, and improving disease monitoring systems will remain vital to sustain and improve current achievements.


Subject(s)
Measles Vaccine/administration & dosage , Measles/epidemiology , Measles/prevention & control , Child, Preschool , Humans , Immunization Programs/organization & administration , Incidence , Infant , Measles/mortality , Population Surveillance , Somalia/epidemiology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...